A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).

The present invention relates to a method and system for obtaining an interaction property between a molecule or biomolecule or particle or bioparticle or nano- or microparticle on the one hand and a target particle on the other hand. The method comprises obtaining potentiometric titration results for a potentiometric measurement during titration of a solution with a titrant, said solution being a solution of one of a ligand of the target particle or said molecule or biomolecule or particle or bioparticle or nano- or microparticle. Said titrant comprises the other of said target particle ligand or said molecule or biomolecule or particle or bioparticle or nano- or microparticle. The method also comprises deriving based on said potentiometric titration results an interaction property between said molecule or biomolecule or particle or bioparticle or nano- or microparticle and said target particle.

The present disclosure discusses a method of separating a sample of tyrosine kinase inhibitors or metabolites of tyrosine kinase inhibitors which includes injecting the sample into the chromatographic system having one or more low-bind coated surfaces along the flow path; flowing the sample through the chromatographic system; separating the sample; and analyzing the separated sample. Consequently, the sample does not bind to the low-binding surface coatings (e.g., alkylsilyl coatings) of the flow path. The applied coating can reduce peak tailing and decrease carryover for tyrosine kinase inhibitor samples during chromatographic analysis.

The present disclosure discusses a method of separating a sample of tyrosine kinase inhibitors or metabolites of tyrosine kinase inhibitors which includes injecting the sample into the chromatographic system having one or more low-bind coated surfaces along the flow path; flowing the sample through the chromatographic system; separating the sample; and analyzing the separated sample. Consequently, the sample does not bind to the low-binding surface coatings (e.g., alkylsilyl coatings) of the flow path. The applied coating can reduce peak tailing and decrease carryover for tyrosine kinase inhibitor samples during chromatographic analysis.

In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti-TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNFα drug during the course of anti-TNFα drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNFα drug in a subject during the course of anti-TNFα drug therapy. Systems for predicting anti-TNFα drug levels and the likelihood of autoantibody formation during the course of anti-TNFα drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNFα drug therapy.

In one configuration, a handheld compound tester to process and detect presence of a compound in a tablet is disclosed. The handheld compound tester may include a sampling chamber configured to receive a tablet and a lid couplable with the sampling chamber. The coupling of the lid with the sampling chamber may cause cutting of the tablet. A liquid may be added inside the sampling chamber to create a mixture with segments of the tablet. The mixture may be then received by a housing adjoining the sampling chamber. A test strip disposed within the housing, upon contacting the mixture, may be configured to indicate a presence of the compound in the mixture.

A detection kit suitable for detecting a target in a sample is provided. The detection kit includes a syringe, a first reaction container, a second reaction container, and a plurality of fluorescent substances. The syringe is loaded with first organic solvent. The first reaction container is connected to the syringe and is loaded with the sample. The second reaction container is connected to the first reaction container and is loaded with second organic solvent. The fluorescent substances are dispersed in the second organic solvent and emit fluorescence. When the target in the sample is dissolved in the first organic solvent and reacts with the fluorescent substances in the second organic solvent, the fluorescence emitted by the fluorescent substances is quenched.

A detection kit suitable for detecting a target in a sample is provided. The detection kit includes a syringe, a first reaction container, a second reaction container, and a plurality of fluorescent substances. The syringe is loaded with first organic solvent. The first reaction container is connected to the syringe and is loaded with the sample. The second reaction container is connected to the first reaction container and is loaded with second organic solvent. The fluorescent substances are dispersed in the second organic solvent and emit fluorescence. When the target in the sample is dissolved in the first organic solvent and reacts with the fluorescent substances in the second organic solvent, the fluorescence emitted by the fluorescent substances is quenched.

A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).